American Journal of Transplantation最新文献_第10页

Ten Year Follow-up After Face Transplantation - a Single Center Retrospective Cohort Study. 面部移植术后十年随访--一项单中心回顾性队列研究。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2024-10-14 DOI: 10.1016/j.ajt.2024.10.007

Lioba Huelsboemer,Martin Kauke-Navarro,Sam Boroumand,Neil Parikh,Helia Hosseini,Catherine T Yu,Viola A Stögner,Christine Ko,Bridget Perry,Richard N Formica,Peter Hung,Amit Mahajan,Jamil R Azzi,George F Murphy,Bohdan Pomahac

{"title":"Ten Year Follow-up After Face Transplantation - a Single Center Retrospective Cohort Study.","authors":"Lioba Huelsboemer,Martin Kauke-Navarro,Sam Boroumand,Neil Parikh,Helia Hosseini,Catherine T Yu,Viola A Stögner,Christine Ko,Bridget Perry,Richard N Formica,Peter Hung,Amit Mahajan,Jamil R Azzi,George F Murphy,Bohdan Pomahac","doi":"10.1016/j.ajt.2024.10.007","DOIUrl":"https://doi.org/10.1016/j.ajt.2024.10.007","url":null,"abstract":"Face transplantation has emerged as reconstructive option for the most challenging facial deformities. A comprehensive analysis of functional outcomes, medical complications, incidence of malignancy, and chronic rejection in face transplantation recipients over an extended follow-up period has not yet been published leaving a notable gap in the literature. We retrospectively collected data of morbidity, rejection, vasculopathy, metabolic side effects, as well as functional outcome of sensory return, facial motor function, and speech from nine patients who underwent face transplantation at Brigham and Women´s Hospital (Boston, USA) between 2009 - 2020. The median follow-up was 120 months (54 - 154 months). Four grafts (40%) developed signs of clinical and histopathological chronic rejection without evidence of vasculopathy on computer tomography angiograms. Sensory return assessed with WEST-Monofilament showed an increase in six patients (66.7%) and facial expression analysis showed improvement throughout the whole cohort at their most recent follow up. Speech intelligibility was stable or increasing for five patients (55.6%). In conclusion, the long-term outcomes reveal promising results in terms of overall graft retention, and functional recovery. Metabolic, malignant, and infectious complications, as well as graft rejection episodes are expected to occur in this population, and some may be related to patient's age and lifestyle.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142448019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of cyclosporine and tacrolimus after liver transplantation for primary biliary cholangitis: A propensity-score matched intention-to-treat registry study. 原发性胆汁性胆管炎肝移植后环孢素与他克莫司的比较：倾向分数匹配的意向治疗登记研究。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2024-10-12 DOI: 10.1016/j.ajt.2024.10.010

Fredrik Åberg,Ville Sallinen,Samuli Tuominen,Ilkka Helanterä,Arno Nordin

{"title":"Comparison of cyclosporine and tacrolimus after liver transplantation for primary biliary cholangitis: A propensity-score matched intention-to-treat registry study.","authors":"Fredrik Åberg,Ville Sallinen,Samuli Tuominen,Ilkka Helanterä,Arno Nordin","doi":"10.1016/j.ajt.2024.10.010","DOIUrl":"https://doi.org/10.1016/j.ajt.2024.10.010","url":null,"abstract":"The optimal calcineurin inhibitor after liver transplantation (LT) for primary biliary cholangitis (PBC) remains debated. We compared tacrolimus with cyclosporine in a propensity score-matched intention-to-treat analysis from the Scientific Registry of Transplant Recipients. We included adults with PBC who underwent primary LT 1995-2022. Patients with initial cyclosporine treatment were 1:3 matched with those with initial tacrolimus treatment, ensuring exact calendar-period match. Primary outcomes were patient and graft survival. After matching, 579 patients with PBC and initial cyclosporine and 1348 with tacrolimus were well balanced for baseline characteristics. During a median follow-up of 11.1 years, 1044 (54%) deaths and 124 (6%) re-LTs occurred. In the overall matched sample, no significant survival difference emerged between cyclosporine and tacrolimus. However, tacrolimus conferred a survival advantage in some secondary analysis such as LT after year 2000, women, and in a 6-month landmark analysis excluding early post-operative events and calcineurin-inhibitor switches. Cyclosporine did not reduce graft loss from PBC recurrence or affect laboratory markers of recurrence. In conclusion, we found no benefit of starting immunosuppression with cyclosporine after LT for PBC.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"2 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lung Transplant Consortium: Collecting Data to Guide Best Practices 肺移植联盟：收集数据，指导最佳实践。

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2024-10-10 DOI: 10.1016/j.ajt.2024.10.003

By Lara C. Pullen PhD

引用次数: 0

Terminally differentiated effector memory T cells in kidney transplant recipients: New crossroads. 肾移植受者的 TEMRA：新的十字路口。

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2024-10-09 DOI: 10.1016/j.ajt.2024.10.001

Steven Van Laecke, Griet Glorieux

{"title":"Terminally differentiated effector memory T cells in kidney transplant recipients: New crossroads.","authors":"Steven Van Laecke, Griet Glorieux","doi":"10.1016/j.ajt.2024.10.001","DOIUrl":"10.1016/j.ajt.2024.10.001","url":null,"abstract":"Immunosenescence, the age-related dysregulation of innate and adaptive immunity, impairs immune response and increases inflammation, leading to higher infection and cardiovascular risks, particularly outside the field of transplantation. In kidney transplant recipients (KTRs), conditions like cytomegalovirus infection, old age, uremia, smoking, and diabetes, linked to poor outcomes, are associated with enhanced immunosenescence. Recent studies highlight the pathogenic role of cytotoxic T cells, particularly terminally differentiated effector memory T cells that reexpress CD45RA (TEMRA), in graft dysfunction. A higher proportion of circulating CD8+ TEMRA cells is observed in KTRs with chronic rejection. In antibody-mediated rejection, they invade the graft by superior chemotactic properties and binding to human leukocyte antigen (HLA) antibodies through FcγRIIIa (CD16). Also in microvascular inflammation without donor-specific antibodies, and even in patients without rejection but faster decline of kidney function, intragraft CD8+ TEMRA cells were instrumental. CD8+ TEMRA cells may explain the unresolved dismal graft outcomes associated with donor age and cytomegalovirus-serostatus mismatching and could become a novel therapeutic target in KTRs.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142398788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The burden of COVID-19 mortality among solid organ transplant recipients in the United States. 美国实体器官移植受者的 COVID-19 死亡率负担。

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2024-10-09 DOI: 10.1016/j.ajt.2024.10.004

Karena D Volesky-Avellaneda, Ruth M Pfeiffer, Meredith S Shiels, David Castenson, Jonathan M Miller, Jeanny H Wang, Kelly J Yu, Florent Avellaneda, Allan B Massie, Dorry L Segev, Ajay K Israni, Jon J Snyder, Eric A Engels

{"title":"The burden of COVID-19 mortality among solid organ transplant recipients in the United States.","authors":"Karena D Volesky-Avellaneda, Ruth M Pfeiffer, Meredith S Shiels, David Castenson, Jonathan M Miller, Jeanny H Wang, Kelly J Yu, Florent Avellaneda, Allan B Massie, Dorry L Segev, Ajay K Israni, Jon J Snyder, Eric A Engels","doi":"10.1016/j.ajt.2024.10.004","DOIUrl":"10.1016/j.ajt.2024.10.004","url":null,"abstract":"Solid organ transplant recipients (SOTRs) have a heightened risk of adverse coronavirus disease 2019 (COVID-19) outcomes because of immunosuppression and medical comorbidity. We quantified the burden of COVID-19 mortality in United States (US) SOTRs. A sample of deaths documented in the US solid organ transplant registry from June 2020 through December 2022 was linked to the National Death Index to identify COVID-19 deaths and weighted to represent all SOTR deaths during the study period. Among 505 757 SOTRs, 57 575 deaths occurred, and based on the linkage, 12 396 (21.5%) were due to COVID-19. COVID-19 mortality was higher in males (mortality rate ratio [MRR]: 1.13), SOTRs aged 65 years and older (MRR: 1.50 in ages 65-74 vs ages 55-64 years), and non-Hispanic Black and Hispanic SOTRs (MRRs: 1.55 and 1.79 vs non-Hispanic White SOTRs). Kidney and lung recipients had the highest COVID-19 mortality, followed by heart, and then liver recipients. COVID-19 mortality also varied over time and across US states. Overall, SOTRs had a 7-fold increased risk of COVID-19 death compared to the US general population. SOTRs comprised 0.13% of the US population but accounted for 1.46% of all US COVID-19 deaths. SOTRs experience greatly elevated COVID-19 mortality. Clinicians should continue to prioritize COVID-19 prevention and treatment in this high-risk population.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142398789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum and tissue biomarkers of plasma cell-rich rejection in liver transplant recipients. 肝移植受者富含浆细胞排斥反应的血清和组织生物标志物。

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2024-10-09 DOI: 10.1016/j.ajt.2024.10.006

Nivetha Saravanan, Anthony Demetris, Maria Isabel Fiel, Claire Harrington, Nigar Anjuman Khurram, Thomas D Schiano, Josh Levitsky

{"title":"Serum and tissue biomarkers of plasma cell-rich rejection in liver transplant recipients.","authors":"Nivetha Saravanan, Anthony Demetris, Maria Isabel Fiel, Claire Harrington, Nigar Anjuman Khurram, Thomas D Schiano, Josh Levitsky","doi":"10.1016/j.ajt.2024.10.006","DOIUrl":"10.1016/j.ajt.2024.10.006","url":null,"abstract":"The distinction between autoimmune and alloimmune reactions in liver transplant recipients can be challenging. Plasma cell-rich rejection (PCRR), previously known as de novo autoimmune hepatitis or plasma cell hepatitis, is an atypical and underrecognized form of allograft rejection observed post-liver transplantation, often in conjunction with features of T cell-mediated and antibody-mediated rejection. If PCRR is not recognized and treated with prompt immunosuppressive augmentation, patients can develop advanced hepatic fibrosis, necroinflammation, and allograft failure. Given the significant morbidity and mortality associated with PCRR, there exists a need to develop noninvasive biomarkers which can be used in screening, diagnosis, and treatment monitoring of PCRR. This study is a literature review of candidate serum-based and tissue-based biomarkers in adult and pediatric liver transplant PCRR. We also discuss biomarkers from plasma cell-rich processes observed in other disease states and other organ transplant recipients that might be tested in liver transplant PCRR. We conclude with proposed future directions in which biomarker implementation into clinical practice could lead to advances in personalized management of PCRR.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142405746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antiplasma cell antibodies: A new era of human leukocyte antigen antibody control in solid organ transplantation. 抗浆细胞抗体：实体器官移植中 HLA 抗体控制的新时代？

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2024-10-09 DOI: 10.1016/j.ajt.2024.10.005

Sindhu Chandran, Flavio Vincenti

{"title":"Antiplasma cell antibodies: A new era of human leukocyte antigen antibody control in solid organ transplantation.","authors":"Sindhu Chandran, Flavio Vincenti","doi":"10.1016/j.ajt.2024.10.005","DOIUrl":"10.1016/j.ajt.2024.10.005","url":null,"abstract":"New therapies directed against plasma cells such as anti-CD38 antibodies and the bispecific anti-B cell maturation antigen antibodies, represent not only an important advance in the treatment of multiple myeloma but have the potential to change the treatment landscape of other antibody-mediated diseases. In solid organ transplantation, the therapeutic armamentarium targeting humoral alloimmune responses in desensitization of highly sensitized transplant candidates and posttransplant antibody-mediated rejection has lagged behind advances in preventing and treating T cell-mediated rejection. Intravenous immunoglobulin and plasmapheresis are used extensively but have limited efficacy. Currently available anti-CD20 antibodies are only partially effective in achieving B cell depletion and leaving mature plasma cells untouched. Although interleukin 6 plays an important role in the humoral alloimmune response and injury, the benefits of interleukin 6 inhibition have failed to be demonstrated in clinical trials. Even proteasome inhibitors developed specifically to target plasma cells have not fulfilled their promise, due to limited efficacy as single agents. This review focuses on the recent experience with, and potential applicability of, anti-CD38 antibodies in the field of organ transplantation and experimental data supporting their use and development for human leukocyte antigen desensitization and antibody-mediated rejection.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142386568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of COVID-19 vaccines for persons aged ≥6 months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025 对年龄≥6 个月者使用 COVID-19 疫苗：免疫实践咨询委员会的建议 - 美国，2024-2025 年。

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2024-10-05 DOI: 10.1016/j.ajt.2024.10.002

Marcus R. Pereira

引用次数: 0

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2024-10-04 DOI: 10.1016/j.ajt.2024.09.035

Julien Zuber, Juliette Leon, Julie Déchanet-Merville, Hannah Kaminski

{"title":"Belatacept-related cytomegalovirus infection: Advocacy for tailored immunosuppression based on individual assessment of immune fitness.","authors":"Julien Zuber, Juliette Leon, Julie Déchanet-Merville, Hannah Kaminski","doi":"10.1016/j.ajt.2024.09.035","DOIUrl":"10.1016/j.ajt.2024.09.035","url":null,"abstract":"Belatacept, a fusion protein combining cytotoxic T-lymphocyte antigen-4 (CTLA-4) and the Fc region of human IgG1, is increasingly used as a calcineurin inhibitor-sparing regimen in patients with chronic graft dysfunction. Older kidney transplant recipients, particularly from expanded criteria donors, may be switched to belatacept due to poor renal recovery. However, late-onset cytomegalovirus (CMV) reactivation is increasingly reported with this treatment, especially in older patients with graft dysfunction. This suggests a progressive loss of CMV-specific T cell response, potentially driven by T cell exhaustion. Contributing factors include preexisting T cell dysfunction, increased viral antigen exposure, and interference in the PD-L1/PD-1 pathway by belatacept. mTOR inhibitors have shown efficacy in preventing CMV reactivation by reinvigorating CMV-specific T cells. These findings support combining belatacept with mTOR inhibitors in high-risk CMV-seropositive recipients and emphasize the need for personalized immune assessments to guide immunosuppressive strategies.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142379622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unique multidisciplinary approach in living donor liver transplantation to achieve total physiological revascularization in a patient with complete occlusion of portal vein system with combined chronic and subacute thrombosis. 在活体肝移植手术中采用独特的多学科方法，为一名门静脉系统完全闭塞并合并慢性和亚急性血栓形成的患者实现完全生理性血管再通。

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2024-10-04 DOI: 10.1016/j.ajt.2024.09.033

Francesca Albanesi, Jae-Yoon Kim, Kwang-Woong Lee, YoungRok Choi, Nam-Joon Yi, Suk-Kyun Hong, Kyung-Suk Suh

{"title":"Unique multidisciplinary approach in living donor liver transplantation to achieve total physiological revascularization in a patient with complete occlusion of portal vein system with combined chronic and subacute thrombosis.","authors":"Francesca Albanesi, Jae-Yoon Kim, Kwang-Woong Lee, YoungRok Choi, Nam-Joon Yi, Suk-Kyun Hong, Kyung-Suk Suh","doi":"10.1016/j.ajt.2024.09.033","DOIUrl":"10.1016/j.ajt.2024.09.033","url":null,"abstract":"Patients receiving liver transplantation in a setting of complete portal vein (PV) and superior mesenteric vein (SMV) thrombosis (Yerdel grade 4) experience lower outcomes after surgery; prognosis is independently influenced by the portal flow reconstruction technique, showing better outcomes in physiological surgical strategies. We describe a case of living donor liver transplantation in which the patient could not receive common physiological reconstructions preoperatively due to multiple small collaterals and extensive thrombosis down to first branches of SMV. We performed thromboendovenectomy of the PV and SMV first, but acute thrombosis developed recurrently even with interposition venous homograft between pericholedochal collateral vein and proximal recipient PV. Immediate after surgery, an intervention radiologist performed stent insertion into 3 stenotic points. Through multidisciplinary approach, complete physiological recanalization was obtained with normal liver function.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.9,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142378812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0